Comparative efficacy of secukinumab versus tumor necrosis factor inhibitors for Takayasu arteritis: comment on the article by Tian et al

Arthritis & RheumatologyVolume 75, Issue 10 p. 1871-1871 Letter Comparative efficacy of secukinumab versus tumor necrosis factor inhibitors for Takayasu arteritis: comment on the article by Tian et al Kritika Singh, Kritika Singh orcid.org/0000-0002-3814-4179 Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, IndiaSearch for more papers by this authorDurga P. Misra, Corresponding Author Durga P. Misra [email protected] orcid.org/0000-0002-5035-7396 Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, IndiaSearch for more papers by this author Kritika Singh, Kritika Singh orcid.org/0000-0002-3814-4179 Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, IndiaSearch for more papers by this authorDurga P. Misra, Corresponding Author Durga P. Misra [email protected] orcid.org/0000-0002-5035-7396 Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, IndiaSearch for more papers by this author First published: 17 April 2023 https://doi.org/10.1002/art.42533 Author disclosures are available at https://onlinelibrary.wiley.com/doi/10.1002/art.42533. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Supporting Information Filename Description art42533-sup-0001-Disclosureform.pdfPDF document, 230.1 KB Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. References 1Tian X, Li M, Jiang N, et al. Comparative efficacy of secukinumab versus tumor necrosis factor inhibitors for the treatment of Takayasu arteritis. Arthritis Rheumatol 2023; 75: 1415–23. 10.1002/art.42496 CASPubMedWeb of Science®Google Scholar 2Singh K, Rathore U, Rai MK, et al. Novel Th17 lymphocyte populations, Th17.1 and PD1+Th17, are increased in Takayasu arteritis, and both Th17 and Th17.1 sub-populations associate with active disease. J Inflamm Res 2022; 15: 1521–41. 10.2147/JIR.S355881 CASPubMedWeb of Science®Google Scholar 3Zhang J, Zhao L, Wang J, et al. Targeting mechanistic target of rapamycin complex 1 restricts proinflammatory T cell differentiation and ameliorates Takayasu arteritis. Arthritis Rheumatol 2020; 72: 303–15. 10.1002/art.41084 CASPubMedWeb of Science®Google Scholar 4Jiang W, Sun M, Wang Y, et al. Critical role of notch-1 in mechanistic target of rapamycin hyperactivity and vascular inflammation in patients with Takayasu arteritis. Arthritis Rheumatol 2022; 74: 1235–44. 10.1002/art.42103 CASPubMedWeb of Science®Google Scholar 5Ortiz-Fernández L, Carmona EG, Kerick M, et al. Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing. Ann Rheum Dis 2023; 82: 837–47. 10.1136/ard-2022-223697 CASPubMedWeb of Science®Google Scholar 6Ma L, Kong X, Cui X, et al. CYR61/TGF-β axis promotes adventitial fibrosis of Takayasu's arteritis in the IL-17 mediated inflammatory microenvironment. Clin Exp Rheumatol 2020; 38: 1102–11. PubMedWeb of Science®Google Scholar 7Davis PH, Dawson JD, Blecha MB, et al. Measurement of aortic intimal-medial thickness in adolescents and young adults. Ultrasound Med Biol 2010; 36: 560–5. 10.1016/j.ultrasmedbio.2010.01.002 PubMedWeb of Science®Google Scholar 8Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016; 75: 1615–21. 10.1136/annrheumdis-2015-207726 CASPubMedWeb of Science®Google Scholar Volume75, Issue10October 2023Pages 1871-1871 ReferencesRelatedInformation